Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33,276Revenue $M1,551Net Margin (%)16.3Z-Score31.8
Enterprise Value $M31,823EPS $1.3Operating Margin %34.0F-Score6
P/E(ttm))84.4Cash Flow Per Share $0.8Pre-tax Margin (%)33.9Higher ROA y-yN
Price/Book11.610-y EBITDA Growth Rate %0Quick Ratio5.3Cash flow > EarningsY
Price/Sales17.75-y EBITDA Growth Rate %52.4Current Ratio5.6Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %38.3ROA % (ttm)7.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)10.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M198ROI % (ttm)16.0Gross Margin Increase y-yN

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 168.226%Add 240.11%17,094
ALXNRay Dalio 2014-06-30 Reduce-0.03%$139.61 - $170.2
($157.93)
$ 168.226%Reduce -47.72%26,332
ALXNJohn Burbank 2014-06-30 Sold Out -0.01%$139.61 - $170.2
($157.93)
$ 168.226%Sold Out0
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 168.226%New holding, 50371 sh.50,371
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 168.226%New holding, 5026 sh.5,026
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 168.226%New holding, 1318 sh.1,318
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 168.226%New holding, 10218 sh.10,218
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 168.226%Reduce -28.52%5,268,418
ALXNFrank Sands 2013-09-30 Reduce-0.27%$94.34 - $117.28
($109.83)
$ 168.2253%Reduce -10.5%7,540,405
ALXNFrank Sands 2013-03-31 Add0.11%$83.39 - $102.57
($93.13)
$ 168.2281%Add 4.23%8,420,336
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 168.2281%Sold Out0
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 168.2271%New holding, 12977 sh.12,977
ALXNFrank Sands 2012-06-30 Add0.27%$83.74 - $98.82
($91.04)
$ 168.2285%Add 6.43%9,739,804
ALXNGeorge Soros 2012-06-30 Sold Out -0.07%$83.74 - $98.82
($91.04)
$ 168.2285%Sold Out0
ALXNGeorge Soros 2012-03-31 Buy 0.07%$70.29 - $94.31
($75.85)
$ 168.22122%New holding, 50000 sh.50,000
ALXNJoel Greenblatt 2011-09-30 Sold Out -0.0882%$47.81 - $66.99
($56.19)
$ 168.22199%Sold Out0
ALXNJoel Greenblatt 2011-06-30 Buy 0.09%$44.61 - $52.195
($47.91)
$ 168.22251%New holding, 13417 sh.13,417
ALXNGeorge Soros 2011-06-30 Sold Out $44.61 - $52.195
($47.91)
$ 168.22251%Sold Out0
ALXNGeorge Soros 2011-03-31 Add$20.14 - $24.93
($22.51)
$ 168.22647%Add 90.48%4,000
ALXNGeorge Soros 2010-12-31 Reduce$31.78 - $41.17
($36.65)
$ 168.22359%Reduce -87.61%4,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALXN Joel Greenblatt 2014-06-3017,0940.010.03+240.11%
ALXN Frank Sands 2014-06-305,279,7822.672.1+0.22%
ALXN Ron Baron 2014-06-3010,1450.010.01-0.71%
ALXN Ray Dalio 2014-06-3026,3320.010.03-47.72%
ALXN John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELL LEONARDCEO 2014-08-15Sell70,000$167.99-0.9view
BELL LEONARDCEO 2014-08-13Sell105,000$160.713.58view
SQUINTO STEPHEN PEVP, Chief Global Ops. Officer 2014-08-04Sell1,662$157.425.75view
Hallal DavidEVP, Chief Commercial Officer 2014-08-04Sell1,349$1585.36view
BELL LEONARDCEO 2014-08-04Sell5,145$157.885.44view
Sinha VikasEVP & CFO 2014-08-04Sell1,525$157.825.48view
Carmichael ClareSVP, Chief HR Officer 2014-08-04Sell184$158.235.21view
BELL LEONARDCEO 2014-07-30Sell127,289$162.932.17view
BELL LEONARDCEO 2014-06-20Sell90,280$163.61.75view
MACKAY MARTINEVP & Global Head of R&D 2014-06-12Sell25,000$166.420.03view

Press Releases about ALXN :

    Quarterly/Annual Reports about ALXN:

    News about ALXN:

    Articles On GuruFocus.com
    Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
    Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
    Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Six High-Impact Sells - Viking Global Investors Aug 26 2013 
    CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 
    Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
    fv 107 Apr 01 2013 
    Weekly Top Insider Sells: GOOG, KSS, ALXN, and QCOM Sep 03 2012 
    Weekly Top Insider Sells: GOOG, YHOO, ALXN, and CTL Jun 04 2012 


    More From Other Websites
    Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Aug 20 2014
    Jazz, Celgene Lead Top 4 Drugmaker Profit Margins Aug 18 2014
    Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014
    [video] Red hot biotech stocks Aug 14 2014
    Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the... Aug 14 2014
    Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the... Aug 13 2014
    GW Pharma, Insys Face Off In Cannabis Drug Space Aug 08 2014
    Today's Stocks Driving Success For The Health Care Sector Aug 08 2014
    Wall Street Transcript Interview with Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics... Aug 08 2014
    NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Aug 07 2014
    Politicians Shouldn't Question Drug Costs But Rather Their Value. Lessons From Soliris And Sovaldi. Aug 04 2014
    European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of... Aug 01 2014
    European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of... Aug 01 2014
    Many Leading Stocks Damaged As Market Tumbles Broadly Jul 31 2014
    ALEXION PHARMACEUTICALS INC Financials Jul 31 2014
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 30 2014
    Biotech ETF Price Swings May Signal Need For Caution Jul 28 2014
    Midday movers: Cummins, Dollar Tree, Zillow & More Jul 28 2014
    ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Jul 25 2014
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 24 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide